Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Sells $1,042,842.87 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High sold 29,787 shares of the stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $35.01, for a total value of $1,042,842.87. Following the sale, the chief operating officer now owns 148,792 shares of the company’s stock, valued at $5,209,207.92. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Susanna Gatti High also recently made the following trade(s):

• On Monday, June 24th, Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock. The stock was sold at an average price of $35.33, for a total value of $359,058.79.
• On Wednesday, June 12th, Susanna Gatti High sold 40,000 shares of Dyne Therapeutics stock. The stock was sold at an average price of $33.36, for a total value of $1,334,400.00.
• On Monday, June 10th, Susanna Gatti High sold 80,000 shares of Dyne Therapeutics stock. The stock was sold at an average price of $30.24, for a total value of $2,419,200.00.
• On Thursday, May 16th, Susanna Gatti High sold 2,738 shares of Dyne Therapeutics stock. The stock was sold at an average price of $28.27, for a total value of $77,403.26.

Dyne Therapeutics Stock Up 1.7 %

Dyne Therapeutics stock opened at $35.63 on Tuesday. Dyne Therapeutics, Inc. has a 52 week low of $6.40 and a 52 week high of $36.60. The company’s 50 day moving average price is $29.19 and its two-hundred day moving average price is $24.03. The stock has a market cap of $3.11 billion, a P/E ratio of -8.97 and a beta of 1.06.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Thursday, May 2nd. The company reported ($0.81) EPS for the quarter, hitting the consensus estimate of ($0.81). On average, equities analysts anticipate that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on DYN shares. Jefferies Financial Group raised their target price on Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, May 20th. Stifel Nicolaus raised their target price on Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Piper Sandler raised their target price on Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. HC Wainwright raised their target price on Dyne Therapeutics from $36.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, May 20th. Finally, Morgan Stanley assumed coverage on Dyne Therapeutics in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $40.78.

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds have recently modified their holdings of the company. Fcpm Iii Services B.V. bought a new stake in shares of Dyne Therapeutics in the 4th quarter worth approximately $81,543,000. RA Capital Management L.P. bought a new stake in shares of Dyne Therapeutics in the 1st quarter worth approximately $140,666,000. Vanguard Group Inc. raised its holdings in shares of Dyne Therapeutics by 47.7% in the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after purchasing an additional 1,110,629 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Dyne Therapeutics by 23,512.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock worth $75,915,000 after purchasing an additional 2,663,910 shares during the period. Finally, Braidwell LP raised its holdings in shares of Dyne Therapeutics by 32.2% in the 3rd quarter. Braidwell LP now owns 1,821,972 shares of the company’s stock worth $16,325,000 after purchasing an additional 444,100 shares during the period. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.